|
|
Blood, 1 May 2006, Vol. 107, No. 9, pp. 3733-3737.
Prepublished online as a Blood First Edition Paper on December 22, 2005; DOI 10.1182/blood-2005-07-2933.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major
Caterina Borgna-Pignatti,
Maria Domenica Cappellini,
Piero De Stefano,
Giovanni Carlo Del Vecchio,
Gian Luca Forni,
Maria Rita Gamberini,
Roberta Ghilardi,
Antonio Piga,
Maria Antonietta Romeo,
Huaqing Zhao, and
Avital Cnaan
From the Clinica Pediatrica of the University of Ferrara, Italy; Clinica Pediatrica of the University of Torino, Italy; Clinica Pediatrica of the University of Catania, Italy; Clinica Pediatrica of the University of Milano, Italy; Clinica Pediatrica of the University of Bari, Italy; Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy; Divisione Pediatrica, Ferrara Hospital, Italy; Ospedali Galliera, Genova, Italy; Centro Anemie Congenite Ospedale Maggiore Policlinico IRCCS, Milan, Italy; and Division of Biostatistics and Epidemiology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia.
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995, to December 31, 2003. All patients with thalassemia major treated in 7 Italian centers who were born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients, and 157 patients received deferiprone for part of the time. A total of 3610 patient-years were observed on DFO and 750 on deferiprone. At baseline, the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least 18 months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Daar, A. V. Pathare, R. Jain, S. A. Zadjali, and D. J. Pennell
T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman
Haematologica,
January 1, 2009;
94(1):
140 - 141.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Vichinsky
Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia
Pediatrics,
June 1, 2008;
121(6):
1253 - 1256.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-Y. Au, W. W.-m. Lam, W. W.C. Chu, H.-L. Yuen, A. S.-C. Ling, R. C.-H. Li, H. M.-H. Chan, H. K.-K. Lee, M.-F. Law, H. S. Y. Liu, et al.
A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong
Haematologica,
May 1, 2008;
93(5):
784 - 786.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Angelucci, G. Barosi, C. Camaschella, M. D. Cappellini, M. Cazzola, R. Galanello, M. Marchetti, A. Piga, and S. Tura
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders
Haematologica,
May 1, 2008;
93(5):
741 - 752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah
The Role of Iron in Diabetes and Its Complications
Diabetes Care,
July 1, 2007;
30(7):
1926 - 1933.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Boddaert, K. H. Le Quan Sang, A. Rotig, A. Leroy-Willig, S. Gallet, F. Brunelle, D. Sidi, J.-C. Thalabard, A. Munnich, and Z. I. Cabantchik
Selective iron chelation in Friedreich ataxia: biologic and clinical implications
Blood,
July 1, 2007;
110(1):
401 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.A. Tanner, R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, et al.
A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance
Circulation,
April 10, 2007;
115(14):
1876 - 1884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fabio, F. Minonzio, P. Delbini, A. Bianchi, and M. D. Cappellini
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)
Blood,
January 1, 2007;
109(1):
362 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Glickstein, R. B. El, G. Link, W. Breuer, A. M. Konijn, C. Hershko, H. Nick, and Z. I. Cabantchik
Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences
Blood,
November 1, 2006;
108(9):
3195 - 3203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
